role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising
Crimean-Congo hemorrhagic fever (CCHF) is a disease with high fatality. To demonstrate the effectiveness of ribavirin against CCHF. The first group of 21 patients received ribavirin within 4 days of the onset of symptoms (early use of ribavirin, EUR); the second group of 20 patients received ribavir...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical microbiology & infectious diseases 2009-08, Vol.28 (8), p.929-933 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 933 |
|---|---|
| container_issue | 8 |
| container_start_page | 929 |
| container_title | European journal of clinical microbiology & infectious diseases |
| container_volume | 28 |
| creator | Tasdelen Fisgin, N Ergonul, O Doganci, L Tulek, N |
| description | Crimean-Congo hemorrhagic fever (CCHF) is a disease with high fatality. To demonstrate the effectiveness of ribavirin against CCHF. The first group of 21 patients received ribavirin within 4 days of the onset of symptoms (early use of ribavirin, EUR); the second group of 20 patients received ribavirin >=5 days after the onset of the symptoms of the disease (late use of ribavirin, LUR); and the last group of 11 patients did not receive ribavirin (no use of ribavirin, NUR). At 5-10 days from the onset of symptoms the mean platelet counts of the patients in the EUR group were significantly higher than those of the patients in LUR group, and at 7-9 days, they were significantly higher than that of the patients in the NUR group. The mean aspartate transferase levels in the EUR group were significantly lower than of the NUR group on days 8 and 9, and the mean alanine transferase level was significantly lower on day 8 after the onset of the symptoms. There is a beneficial effect of ribavirin if given at an early phase of the CCHF. We suggest ribavirin use especially in the early phase of the disease. |
| doi_str_mv | 10.1007/s10096-009-0728-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_954594147</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>954594147</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-2c438763d81d118c9f00e5a71ea5ec51762eddf77c5ce66a244f7f2353e667643</originalsourceid><addsrcrecordid>eNp9kF9rFDEUxYNY7Fr9AL5oEMSnaP5npm-yqC0U-qB98iGkmZvZKbOTNdkp7Lf3LrNY8EFIbgj5nXtuDiFvBP8kOHefK9bWMiyMO9kw-YyshFaGaeXUc7LirdKsdVKdk5e1PnDUNM69IOeiVVxw7VbkV8kj0JxoGe7D41CGieLab-C4S9gdjm_rMmwhTGydpz7TDWxzKZvQD5EmeIRySSGU8UDnCnSodFfydqjD1L8iZymMFV6fzgty9-3rz_UVu7n9fr3-csOiNmbPZNSqcVZ1jeiEaGKbOAcTnIBgIBrhrISuS85FE8HaILVOLkllFN6c1eqCfFz6ovPvGereo3-EcQwT5Ln61mjTaqEdku__IR_yXCYczkvR2EYaYxESCxRLrrVA8jv8fygHL7g_5u6X3D0Wf8zdS9S8PTWe77fQPSlOQSPw4QSEGsOYSpjiUP9y6N5oIQxycuEqPk09lKcJ_-f-bhGlkH3oCza--yG5QG9MSFqh_gApf6Jn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218682556</pqid></control><display><type>article</type><title>role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Tasdelen Fisgin, N ; Ergonul, O ; Doganci, L ; Tulek, N</creator><creatorcontrib>Tasdelen Fisgin, N ; Ergonul, O ; Doganci, L ; Tulek, N</creatorcontrib><description>Crimean-Congo hemorrhagic fever (CCHF) is a disease with high fatality. To demonstrate the effectiveness of ribavirin against CCHF. The first group of 21 patients received ribavirin within 4 days of the onset of symptoms (early use of ribavirin, EUR); the second group of 20 patients received ribavirin >=5 days after the onset of the symptoms of the disease (late use of ribavirin, LUR); and the last group of 11 patients did not receive ribavirin (no use of ribavirin, NUR). At 5-10 days from the onset of symptoms the mean platelet counts of the patients in the EUR group were significantly higher than those of the patients in LUR group, and at 7-9 days, they were significantly higher than that of the patients in the NUR group. The mean aspartate transferase levels in the EUR group were significantly lower than of the NUR group on days 8 and 9, and the mean alanine transferase level was significantly lower on day 8 after the onset of the symptoms. There is a beneficial effect of ribavirin if given at an early phase of the CCHF. We suggest ribavirin use especially in the early phase of the disease.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-009-0728-2</identifier><identifier>PMID: 19301047</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Adult ; Aged ; Alanine Transaminase - blood ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - therapeutic use ; Arachnids ; Arboviral haemorrhagic fevers ; Arboviroses ; Aspartate Aminotransferases - blood ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Fatalities ; Female ; Fever ; Hemorrhagic Fever, Crimean - drug therapy ; Human viral diseases ; Humans ; Infectious diseases ; Internal Medicine ; Male ; Medical Microbiology ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Platelet Count ; Ribavirin - therapeutic use ; Time Factors ; Treatment Outcome ; Tropical viral diseases ; Viral diseases</subject><ispartof>European journal of clinical microbiology & infectious diseases, 2009-08, Vol.28 (8), p.929-933</ispartof><rights>Springer-Verlag 2009</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-2c438763d81d118c9f00e5a71ea5ec51762eddf77c5ce66a244f7f2353e667643</citedby><cites>FETCH-LOGICAL-c455t-2c438763d81d118c9f00e5a71ea5ec51762eddf77c5ce66a244f7f2353e667643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10096-009-0728-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10096-009-0728-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21884115$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19301047$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tasdelen Fisgin, N</creatorcontrib><creatorcontrib>Ergonul, O</creatorcontrib><creatorcontrib>Doganci, L</creatorcontrib><creatorcontrib>Tulek, N</creatorcontrib><title>role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>Crimean-Congo hemorrhagic fever (CCHF) is a disease with high fatality. To demonstrate the effectiveness of ribavirin against CCHF. The first group of 21 patients received ribavirin within 4 days of the onset of symptoms (early use of ribavirin, EUR); the second group of 20 patients received ribavirin >=5 days after the onset of the symptoms of the disease (late use of ribavirin, LUR); and the last group of 11 patients did not receive ribavirin (no use of ribavirin, NUR). At 5-10 days from the onset of symptoms the mean platelet counts of the patients in the EUR group were significantly higher than those of the patients in LUR group, and at 7-9 days, they were significantly higher than that of the patients in the NUR group. The mean aspartate transferase levels in the EUR group were significantly lower than of the NUR group on days 8 and 9, and the mean alanine transferase level was significantly lower on day 8 after the onset of the symptoms. There is a beneficial effect of ribavirin if given at an early phase of the CCHF. We suggest ribavirin use especially in the early phase of the disease.</description><subject>Adult</subject><subject>Aged</subject><subject>Alanine Transaminase - blood</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Arachnids</subject><subject>Arboviral haemorrhagic fevers</subject><subject>Arboviroses</subject><subject>Aspartate Aminotransferases - blood</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Fatalities</subject><subject>Female</subject><subject>Fever</subject><subject>Hemorrhagic Fever, Crimean - drug therapy</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Count</subject><subject>Ribavirin - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tropical viral diseases</subject><subject>Viral diseases</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kF9rFDEUxYNY7Fr9AL5oEMSnaP5npm-yqC0U-qB98iGkmZvZKbOTNdkp7Lf3LrNY8EFIbgj5nXtuDiFvBP8kOHefK9bWMiyMO9kw-YyshFaGaeXUc7LirdKsdVKdk5e1PnDUNM69IOeiVVxw7VbkV8kj0JxoGe7D41CGieLab-C4S9gdjm_rMmwhTGydpz7TDWxzKZvQD5EmeIRySSGU8UDnCnSodFfydqjD1L8iZymMFV6fzgty9-3rz_UVu7n9fr3-csOiNmbPZNSqcVZ1jeiEaGKbOAcTnIBgIBrhrISuS85FE8HaILVOLkllFN6c1eqCfFz6ovPvGereo3-EcQwT5Ln61mjTaqEdku__IR_yXCYczkvR2EYaYxESCxRLrrVA8jv8fygHL7g_5u6X3D0Wf8zdS9S8PTWe77fQPSlOQSPw4QSEGsOYSpjiUP9y6N5oIQxycuEqPk09lKcJ_-f-bhGlkH3oCza--yG5QG9MSFqh_gApf6Jn</recordid><startdate>20090801</startdate><enddate>20090801</enddate><creator>Tasdelen Fisgin, N</creator><creator>Ergonul, O</creator><creator>Doganci, L</creator><creator>Tulek, N</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20090801</creationdate><title>role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising</title><author>Tasdelen Fisgin, N ; Ergonul, O ; Doganci, L ; Tulek, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-2c438763d81d118c9f00e5a71ea5ec51762eddf77c5ce66a244f7f2353e667643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alanine Transaminase - blood</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Arachnids</topic><topic>Arboviral haemorrhagic fevers</topic><topic>Arboviroses</topic><topic>Aspartate Aminotransferases - blood</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Fatalities</topic><topic>Female</topic><topic>Fever</topic><topic>Hemorrhagic Fever, Crimean - drug therapy</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Count</topic><topic>Ribavirin - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tropical viral diseases</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tasdelen Fisgin, N</creatorcontrib><creatorcontrib>Ergonul, O</creatorcontrib><creatorcontrib>Doganci, L</creatorcontrib><creatorcontrib>Tulek, N</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tasdelen Fisgin, N</au><au>Ergonul, O</au><au>Doganci, L</au><au>Tulek, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><stitle>Eur J Clin Microbiol Infect Dis</stitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2009-08-01</date><risdate>2009</risdate><volume>28</volume><issue>8</issue><spage>929</spage><epage>933</epage><pages>929-933</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>Crimean-Congo hemorrhagic fever (CCHF) is a disease with high fatality. To demonstrate the effectiveness of ribavirin against CCHF. The first group of 21 patients received ribavirin within 4 days of the onset of symptoms (early use of ribavirin, EUR); the second group of 20 patients received ribavirin >=5 days after the onset of the symptoms of the disease (late use of ribavirin, LUR); and the last group of 11 patients did not receive ribavirin (no use of ribavirin, NUR). At 5-10 days from the onset of symptoms the mean platelet counts of the patients in the EUR group were significantly higher than those of the patients in LUR group, and at 7-9 days, they were significantly higher than that of the patients in the NUR group. The mean aspartate transferase levels in the EUR group were significantly lower than of the NUR group on days 8 and 9, and the mean alanine transferase level was significantly lower on day 8 after the onset of the symptoms. There is a beneficial effect of ribavirin if given at an early phase of the CCHF. We suggest ribavirin use especially in the early phase of the disease.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>19301047</pmid><doi>10.1007/s10096-009-0728-2</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-9723 |
| ispartof | European journal of clinical microbiology & infectious diseases, 2009-08, Vol.28 (8), p.929-933 |
| issn | 0934-9723 1435-4373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_954594147 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Alanine Transaminase - blood Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - therapeutic use Arachnids Arboviral haemorrhagic fevers Arboviroses Aspartate Aminotransferases - blood Biological and medical sciences Biomedical and Life Sciences Biomedicine Fatalities Female Fever Hemorrhagic Fever, Crimean - drug therapy Human viral diseases Humans Infectious diseases Internal Medicine Male Medical Microbiology Medical sciences Middle Aged Pharmacology. Drug treatments Platelet Count Ribavirin - therapeutic use Time Factors Treatment Outcome Tropical viral diseases Viral diseases |
| title | role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T14%3A54%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=role%20of%20ribavirin%20in%20the%20therapy%20of%20Crimean-Congo%20hemorrhagic%20fever:%20early%20use%20is%20promising&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=Tasdelen%20Fisgin,%20N&rft.date=2009-08-01&rft.volume=28&rft.issue=8&rft.spage=929&rft.epage=933&rft.pages=929-933&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-009-0728-2&rft_dat=%3Cproquest_cross%3E954594147%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218682556&rft_id=info:pmid/19301047&rfr_iscdi=true |